Treatment of community-acquired pneumonia, with special emphasis on gemifloxacin

Therapeutics and Clinical Risk Management

Volumn 3, Issue 3, 2007, Pages 441-448

  Öncü, Serkan ^a  

^a ADNAN MENDERES UNIVERSITY   (Turkey)

Author keywords

Community acquired pneumonia; Gemifloxacin; Treatment

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; FERROUS SULFATE; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SUCRALFATE; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; BACTERICIDAL ACTIVITY; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; ENTEROBACTERIACEAE; ENZYME INHIBITION; FOOD; FOOD DRUG INTERACTION; HAEMOPHILUS INFLUENZAE; HUMAN; IN VITRO STUDY; LEGIONELLA PNEUMOPHILA; LIVER FAILURE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MORBIDITY; MORTALITY; MYCOPLASMA PNEUMONIAE; NAUSEA; NONHUMAN; OUTPATIENT CARE; PHOTOTOXICITY; QT PROLONGATION; RASH; RESPIRATORY VIRUS; REVIEW; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 34547665616     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Ailani RY, Alimchandani A, Hidalgo J, et al. 2002. Cephalosporin-resistant pneumococcal pneumonia:does it, affect outcome? Respir Med, 96:805-11.
2. Allen A, Bygate E, Clark D, et al. 2000a. The effect of food on the bioavailability of oral gemifloxacin in healthy volunteers. Int J Antimicrob Agents, 16:45-50.
3. Allen A, Bygate E, Faessel H, et al. 2000b. The effect of ferrous sulphate and sucralfate on the bioavailability of oral gemifloxacin in healthy volunteers. Int J Antimicrob Agents, 15:283-9.
4. Allen A, Bygate E, Vousden M, et al. 2001. Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers. Antimicrob Agents Chemother, 45:540-5.
5. Allen A, Vousden M, Porter A, et al. 1999. Effect of Maalox on the bioavailability of oral gemifloxacin in healthy volunteers. Chemotherapy, 45:504-11.
6. Appelbaum PC, Gillespie SH, Burley CJ, et al. 2004. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin. Int J Antimicrob Agents, 23:533-46.
7. Arancibia F, Bauer TT, Ewig S, et al. 2002. Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med, 162:1849-58.
8. Ball P. 2000. Quinolone generations:natural history or natural selection? J Antimicrob Chemother, 46(Suppl T1): 17-24.
9. Ball P, File TM, Twynholm M, et al. 2001. Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections. Int J Antimicrob Agents, 18:19-27.
10. Bartlett JG, Dowell SF, Mandell LA, et al. 2000. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis, 31:347-82.
11. Bhavnani SM, Andes DR. 2005. Gemifloxacin for the treatment of respiratory tract infections:in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy, 25:717-40.
12. Broskey J, Coleman K, Gwynn MN, et al. 2000. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae. J Antimicrob Chemother, 45(Suppl 1):95-9.
13. Brueggemann AB, Coffman SL, Rhomberg P, et al. 2002. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob Agents Chemother, 46:680-8.
14. Choi EH, Lee HJ. 1998. Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children. Clin Infect Dis, 26:1346-54.
15. Cizman M, Pokorn M, Seme K, et al. 1999. Influence of increased macrolide consumption on macrolide resistance of common respiratory pathogens. Eur J Clin Microbiol Infect Dis, 18:522-4.
16. Clavo-Sanchez AJ, Giron-Gonzalez JA, Lopez-Prieto D, et al. 1997. Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae:a multicenter study. Clin Infect Dis, 24:1052-9.
17. Corporation OP. 2004. Factive (gemifloxacin) package insert. Med Lett Drugs Ther: 78-9.
18. Davies TA, Kelly LM, Hoellman DB, et al. 2000a. Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis. Antimicrob Agents Chemother, 44:633-9.
19. Davies TA, Kelly LM, Pankuch GA, et al. 2000b. Antipneumococcal activities of gemifloxacin compared to those of nine other agents. Antimicrob Agents Chemother, 44:304-10.
20. Deeks SL, Palacio R, Ruvinsky R, et al. 1999. Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. The Streptococcus pneumoniae Working Group. Pediatrics, 103:409-13.
21. Deshpande LM, Jones RN. 2000. Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquirod respiratory tract infections in the United States (1999). Diagn Microbiol Infect Dis, 37:139-42.
22. File TM. 2003. Community-acquired pneumonia. Lancet, 362:1991-2001.
23. File TM Jr, Niederman MS. 2004. Antimicrobial therapy of community-acquired pneumonia. Infect Dis Clin North Am, 18:993-1016, xi.
24. File TM Jr, Schlemmer B, Garau J, et al. 2001. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. J Antimicrob Chemother, 48:67-74.
25. File TM Jr, Tillotson GS. 2004. Gemifloxacin:a new, potent fluoroquinolone for the therapy of lower respiratory tract infections. Expert Rev Anti Infect Ther, 2:831-43.
26. Fine MJ, Auble TE, Yealy DM, et al. 1997. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med, 336:243-50.
27. Firsov AA, Zinner SH, Lubenko I, et al. 2000. Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model:prediction of the equivalent AUC/MIC breakpoints and doses. Int J Antimicrob Agents, 16:407-14.
28. Fogarty C, Goldschmidt R, Bush K. 2000. Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin Infect Dis, 31:613-5.
29. Forward KR. 1999. The epidemiology of penicillin resistance in Streptococcus pneumoniae. Semin Respir Infect, 14:243-54.
30. Friedland IR. 1995. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease. Pediatr Infect Dis J, 14:885-90.
31. Garau J. 2005. Role of beta-lactam agents in the treatment of community-acquired pneumonia. Eur J Clin Microbiol Infect Dis, 24:83-99.
32. Garcia-Rodriguez JA, Munoz Bellido JL. 2000. The role of fluoroquinolones in respiratory tract infections:conununity acquired pneumonia. Int J Antimicrob Agents, 16:281-5.
33. Gillespie SH, Voelker LL, Ambler JE, et al. 2003. Fluoroquinolone resistance in Streptococcus pneumoniae:evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation. Microb Drug Resist, 9:17-24.
34. Gillespie SH, Voelker LL, Dickens A. 2002. Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae. Microb Drug Resist, 8:79-84.
35. Gotfried MH. 2000. Comparison of bacteriologic eradication of Streptococcus pneumoniae by clarithromycin and reports of increased antimicrobial resistance. Clin Ther, 22:2-14.
36. Heaton VJ, Ambler JE, Fisher LM. 2000. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro. Antimicrob Agents Chemother, 44:3112-7.
37. Heaton VJ, Goldsmith CE, Ambler JE, et al. 1999. Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms. Antimicrob Agents Chemother, 43:2998-3000.
38. Hong CY. 2001. Discovery of gemifloxacin (Factive, LB20304a): a quinolone of a new generation. Farmaco, 56:41-4.
39. Johnson AP, Sheppard CL, Harnett SJ, et al. 2003. Emergence of a fluoroquinolone-resistant strain of Streptococcus pneumoniae in England. J Antimicrob Chemother, 52:953-60.
40. Jokinen C, Heiskanen L, Juvonen H, et al. 2001. Microbial etiology of community-acquired pneumonia in the adult population of 4 municipalities in eastern Finland. Clin Infect Dis, 32:1141-54.
41. Kelley MA, Weber DJ, Gilligan P, et al. 2000. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis, 31:1008-11.
42. Leophonte P, File T, Feldman C. 2004. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir Med, 98:708-20.
43. Lewis RJ, Tsai FT, Wigley DB. 1996. Molecular mechanisms of drug inhibition of DNA gyrase. Bioessays, 18:661-71.
44. Lim WS, Macfarlane JT, Boswell TC, et al. 2001. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax, 56:296-301.
45. Lim WS, van der Eerden MM, Laing R, et al. 2003. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax, 58:377-82.
46. Lode H, File TM Jr, Mandell L, et al. 2002. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia:a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin Ther, 24:1915-36.
47. Lonks JR, Garau J, Gomez L, et al. 2002. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis, 35:556-64.
48. Marchese A, Debbia EA, Schito GC. 2000. Comparative in vitro potency of gemifloxacin against European respiratory tract pathogens isolated in the Alexander Project. J Antimicrob Chemother, 46(Suppl T1):11-5.
49. McCloskey L, Moore T, Niconovich N, et al. 2000. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA. J Antimicrob Chemother, 45(Suppl 1):13-21.
50. Morrissey I, George JT. 2000. Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones. J Antimicrob Chemother, 45(Suppl 1): 101-6.
51. Musher DM, Dowell ME, Shortridge VD, et al. 2002. Emergence of macrolide resistance during treatment of pneumococoal pneumonia. N Engl J Med, 346:630-1.
52. Niederman MS, Mandell LA, Anzueto A, et al. 2001. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med, 163:1730-54.
53. O'Donnell JA, Gelone SP. 2000. Fluoroquinolones. Infect Dis Clin North Am 14:489-513, xi.
54. Oncu S, Erdem H, Pahsa A. 2005. Therapeutic options for pneumococcal pneumonia in Turkey. Clin Ther, 27:674-83.
55. Oncu S, Punar M, Eraksoy H. 2004. Comparative activities of beta-lactam antibiotics and quinolones for invasive Streptococcus pneumoniae isolates. Chemotherapy, 50:98-100.
56. Oster P, Zanchi A, Cresti S, et al. 1999. Patterns of macrolide resistance determinants among community-acquired Streptococcus pneumoniae isolates over a 5-year period ofdecreased macrolide susceptibility rates. Antimicrob Agents Chemother, 43:2510-2.
57. Paganin F, Lilienthal F, Bourdin A, et al. 2004. Severe community-acquired pneumonia:assessment of microbial aetiology as mortality factor. Eur Respir J 24:779-85.
58. Pallares R, Fenoll A, Linares J. 2003. The epidemiology of antibiotic resistance in Streptococcus pneumoniae and the clinical relevance of resistance to cephalosporins, macrolides and quinolones. Int J Antimicrob Agents, 22(Suppl 1):S15-24; discussion S25-6.
59. Pallares R, Linares J, Vadillo M, et al. 1995. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med, 333:474-80.
60. Shortridge VD, Doern GV, Brueggemann AB, et al. 1999. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. Clin Infect Dis, 29:1186-8.
61. Van Kerkhoven D, Peetermans WE, Verbist L, et al. 2003. Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactams. J Antimicrob Chemother, 51:691-6.
62. Yague G, Morris JE, Pan XS, et al. 2002. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones. Antimicrob Agents Chemother, 46:413-9.
63. Yoo BK, Triller DM, Yong CS, et al. 2004. Gemifloxacin:a new fluoroquinolone approved for treatment of respiratory infections. Ann Pharmacother, 38:1226-35.
64. Yu VL, Chiou CC, Feldman C, et al. 2003. An international prospective study of pneumococcal bacteremia:correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis, 37:230-7.
65. Zhanel GG, Noreddin AM. 2001. Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. Curr Opin Pharmacol, 1:459-63.